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Abstract
Impaired function of NPC1 or NPC2 lysosomal proteins leads to the intracellular accumula-
tion of unesterified cholesterol, the primary defect underlying Niemann-Pick type C (NPC)
disease. In addition, glycosphingolipids (GSLs) accumulate in lysosomes as well. Intralyso-
somal lipid accumulation triggers the activation of a set of genes, including potential bio-
markers. Transcript levels of Gpnmb have been shown to be elevated in various tissues of
an NPC mouse model. We speculated that Gpnmb could serve as a marker for visceral lipid
accumulation in NPC disease. We report that Gpnmb expression is increased at protein
level in macrophages in the viscera of Npc1nih/nih mice. Interestingly, soluble Gpnmb was
also found to be increased in murine and NPC patient plasma. Exposure of RAW264.7 mac-
rophages to the NPC-phenotype-inducing drug U18666A also upregulated Gpnmb expres-
sion. Inhibition of GSL synthesis with the glucosylceramide synthase (GCS) inhibitor N-
butyl-1-deoxynojirimycin prevented U18666A-induced Gpnmb induction and secretion. In
summary, we show that Gpnmb is upregulated in NPC mice and patients, most likely due to
GSL accumulation.
Introduction
Niemann-Pick type C (NPC) disease is an autosomal recessive neurovisceral lysosomal storage
disorder (LSD) with an estimated minimal incidence of 1/120 000 live births [1]. Loss-of-func-
tion mutations in the transmembrane protein NPC1 account for approximately 95% of the
NPC cases, with the remainder involving the soluble protein NPC2 [2]. NPC1 and NPC2 are
thought to function cooperatively in the transport of cholesterol from late endosomal/lyso-
somal (LE/L) compartment to other cellular sites [3]. Malfunction of either protein leads to the
accumulation of unesterified cholesterol in LE/L. Glycosphingolipid (GSL) accumulation also
occurs, most likely as a result of impaired activity of multiple lysosomal hydrolases [4–6].
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The disease manifestation is heterogeneous with respect to phenotype, progression and age
of onset. Four different forms can be classified based on the onset and severity: the early-infan-
tile form, in which patients usually die before the age of 5; the late-infantile form with severe
liver and pulmonary affection; the juvenile or classic form, in which motor skill and neurode-
generation disorders manifest in middle to late childhood patients; the adult form, in which
patients present neurologic disease and progressive dementia [1]. The only therapy for NPC
approved by the European Medical Association (EMA) is oral administration of the glucosyl-
ceramide synthase (GCS) inhibitor N-butyl-1-deoxynojirimycin (NB-DNJ, Zavesca) [7].
NB-DNJ inhibits the synthesis of glucosylceramide (GlcCer), the building-block of more com-
plex GSLs, but does not directly target the unesterified cholesterol accumulation.
The spontaneously occurring BALB/cNctr-Npc1m1N/J (Npc1nih/nih) mouse strain is defined
by an early truncation of the NPC1 protein [8]. This strain displays all the hallmarks of the
human infantile form of NPC, including increased hepatic fibrosis and oxidative stress mark-
ers, as well as progressive hepatomegaly due to the accumulation of free cholesterol [9,10]. The
Npc1nih/nih mice also demonstrate alterations in immune cell phenotypes in the brain, liver and
spleen [10–14]. For instance, macrophage foam cells are present in the liver [15] and natural
killer T cell development is impaired [16]. Recently it has been demonstrated that inflamma-
tion occurs secondarily to neuronal and epithelial cell dysfunction in NPC mice [11].
Two diagnostic standards for NPC1 are currently used. The first one requires a skin biopsy
and subsequent demonstration of lysosomal cholesterol accumulation in cultured fibroblasts
by filipin staining. The second procedure is based on demonstration of elevated plasma oxy-
sterol levels, requiring advanced quantitative mass spectrometry [17]. The lack of more conve-
nient blood based diagnostic markers for NPC triggered various genomic and lipid-based
approaches searching for new serum biomarkers in NPC mouse models [18–20]. Recently, the
lipid lyso-sphingomyelin and its isoform lyso-sphingomyelin-509 have been shown to have
great potential as diagnostic biomarker for NPC [21,22]. Genomic studies yielded various can-
didates, including cathepsins, lysozyme and galectin-3 [18–20,23,24]. Glycoprotein nonmeta-
static melanoma protein B (Gpnmb) mRNA was also found to be increased in Npc1nih/nih
mouse brain, liver and spleen [18].
Although Gpnmb is a membrane protein, it has been observed that cell types such as C2C12
myoblasts, melanocytic cells, astrocytes and breast cancer cells release by shedding a soluble
form of Gpnmb [25–28]. Here we investigated the potential of Gpnmb as a plasma marker to
follow disease progression in mouse models or previously diagnosed cases of NPC.
Materials and Methods
Cell culture
RAW264.7 cells were obtained from the American Type Culture Collection and were cultured
in DMEM (Dulbecco’s Modified Eagle Medium)/10% FCS (fetal calf serum) supplemented
with penicillin/streptomycin. In vitro the NPC phenotype was induced with U18666A (Sigma)
at concentrations ranging from 1–10 μM; N-butyl-1-deoxynojirimycin (Sigma) was used at
250 μM to block GSL synthesis.
Animals
Npc1nih/nih and mice Npc1nmf164, along with wild-type littermates (Npc1+/+), were generated by
crossing Npc1+/nih or Npc1+/nmf164 males and females in-house. The heterozygous BALB/c
Nctr-Npc1m1N/J mice (stock number 003092) and C57BL/6J-Npc1nmf164/J (stock number
004817) were obtained from The Jackson Laboratory (Bar Harbor, USA). Mouse pups were
genotyped according to published protocols [8,29]. Mice (± 3 weeks old) received the rodent
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AM-II diet (Arie Blok Diervoeders, Woerden, The Netherlands). The mice were housed at the
Institute Animal Core Facility in a temperature- and humidity-controlled room with a 12-h
light/dark cycle and given free access to food and water ad libitum. All animal protocols were
approved by the Institutional Animal Welfare Committee of the Academic Medical Centre
Amsterdam in the Netherlands (DBC101698 and DBC17AC). Animals were first anesthetized
with a dose of Hypnorm (0.315 mg/mL phenyl citrate and 10 mg/mL fluanisone) and Dormi-
cum (5 mg/mL midazolam) according to their weight. The given dose was 80 μL/10 g body-
weight. Animals were sacrificed by cervical dislocation. Organs were collected by surgery and
rinsed with PBS. Each one was sliced in half: one part was directly snap-frozen in liquid nitro-
gen and stored at -80°C for lipid and gene expression analysis and the other half was conserved
in phosphate-buffered formalin for posterior histologic analysis. Later, homogenates for lipid
analysis were made from the frozen material in 25 mM potassium phosphate buffer, pH 6.5,
supplemented with 0.1% (v/v) Triton X-100 and protease inhibitors.
Patients
EDTA plasma samples of 17 NPC patients and 8 NPC carriers were collected prior to therapy
initiation at the Unidad de Investigación Traslacional in Zaragoza. The status of affected or car-
rier of NPC disease was determined after the exomic sequencing of NPC1 and NPC2 genes,
according to the presence of two or one mutations, respectively. Filipin stainings of fibroblasts
were conducted to complete the diagnosis study. Plasma samples were stored frozen at -20°C
until further use. Plasma samples of 5 male and 4 female control subjects were collected at the
Academic Medical Center. Plasma samples were stored frozen at -20°C until further use.
Ethics statement
A written informed consent was obtained from each patient or their guardian. The study proto-
col was approved by the Ethics Committee for Clinical Investigation of Aragon (CEICA) in
Spain, and the study was carried out in accordance with the ethical standards of the Declaration
of Helsinki. A written informed consent was also obtained from each healthy volunteer. The
study was approved by the Medical Ethics Committee of the Academic Medical Center in
Amsterdam, the Netherlands, and was conducted according to the Declaration of Helsinki
principles.
Immunohistochemistry
For histology, 4-μm-thick sections were cut from formalin-fixed, paraffin-embedded tissue and
mounted on glass slides. After deparaffinization and rehydration, sections were stained with
hematoxylin and eosin (HE). For immunohistology, heat-induced epitope retrieval (HIER) of
rehydrated sections was performed, using 10 mM citrate, pH 6.0, for 10 min at 98°C. After
washing, the sections were subsequently incubated with antigen affinity-purified polyclonal
goat IgG anti-Gpnmb (AF2330; R&D Systems, Abingdon, UK), washed, incubated with rabbit
anti-goat IgG (6160–01; Southern Biotech, Birmingham, AL, USA), washed, and incubated
with intestinal alkaline phosphatase-conjugated poly-AP goat anti-rabbit IgG (BrightVision;
ImmunoLogic, Klinipath, Duiven, The Netherlands). Intestinal AP activity was detected using
VectorBlue substrate (SK-5300; Vector Laboratories, Burlingame, CA, USA) in presence of 0.2
mM levamisole to inhibit endogenous non-intestinal alkaline phosphatase activity. After wash-
ing, a second HIER was applied to denature and remove all antibodies from the first staining
sequence while leaving the precipitated chromogen unchanged [30]. Subsequently, sections
were incubated with rabbit anti-ionized calcium binding adapter molecule 1 (Iba1) (#019–
19741; WAKO Chemicals, Neuss, Germany), washed, and incubated with poly-AP goat anti-
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rabbit IgG. AP activity was detected using VectorRed substrate (SK-5100; Vector Laboratories)
in presence of 0.2 mM levamisole. Sections were counterstained with methyl green and
mounted with VectaMount (Vector Laboratories). Analysis was performed using brightfield
microscopy (Leica DM5000B) with an HC PLAN APO 20x/0.70 objective. Multispectral data
sets were acquired using a Nuance imaging system (Perkin Elmer, Hopkinton, MA, USA) from
420 to 720 nm at intervals of 10 nm. Spectral libraries for each chromogen were obtained from
single-stained sections and were used to unmix the triple staining patterns. Nuance 3.0.2 soft-
ware was used to display intensity heat maps for single channels and to construct composite
images applying colour universal design.
Measurement of Neutral (Glyco)sphingolipids
Ceramide (Cer), glucosylceramide (GlcCer), lactosylceramide (LacCer) and globotriaosylcera-
mide (Gb3) levels were determined as described previously [31]. Shortly, lipids were extracted
according to Bligh/Dyer et al [32], Chloroform phase was thoroughly dried, and deacylation of
lipids was performed in 0.5 mL of 0.1 M NaOH in methanol in a microwave oven (CEMmicro-
wave Solids/Moisture System SAM-155). Deacylated lipids were derivatized on-line for 30 min
with O-phtaldehyde and separated with a HPLC system (Waters Associates, Milford, USA)
and a Hypersil BDS C18 3 μm, 150 mm x 4.6 mm reverse-phase column (Alltech Inc., USA).
All samples were measured in duplicate (tissues samples) or triplicate (cellular lysates), and in
every run a reference sample was included. Sphingosine levels were measured as described
above, but skipping the deacylation step.
Cholesterol measurement
Total cholesterol levels in liver and spleen homogenates were extracted with chloroform/meth-
anol according to Folch [33] followed by quantification using a colorimetric enzymatic kit
(Biolabo, Maizy, France). Total cholesterol levels in cell lysates were determined using a modi-
fied enzymatic fluorometric assay previously described [34]. Briefly, cells were washed three
times in PBS and lysed in water. Total cholesterol levels in the cell lysates were determined by
incubating samples with 0.03U of cholesterol oxidase (Streptomyces sp., Sigma) and 0.005U of
cholesterol esterase together with peroxidase, taurocholate and homovanillic acid in a 0.1M
MOPS buffer (pH 7.7) containing 0.1% (v/v) Triton X-100. Formed fluorescence was measured
in Synergy HT (Molecular Devices, BioTek Instruments, Winooski, VT, USA) multi-detection
microplate reader with excitation at 320 nm and emission at 440 nm.
Gene expression
Total RNA was extracted from liver and spleen combining the TRIZOL (Invitrogen) reagent
and the nucleospin II extraction kit (Macherey-Nagel) as described previously [35]. RNA con-
centrations were measured using the Nanodrop Spectrophotometer (Nanodrop Technologies).
Equal amounts of RNA were used to synthesize cDNA, according to the manufacturer’s
method (Invitrogen). Gene specific analysis was done by real-time RT-PCR using an iCycler
MyiQTM system (Biorad). Expression levels of Gpnmb (forward 5’-caggaatgatttggg
actgacc-3’; reverse 5’-ccgggaacctgagatgctg-3’), Ccl3 (forward 5’-ccaagtc
ttctcagcgccat-3’ reverse 5’-tcttccggctgtaggagaagc-3’), CtsD (forward 5’-
gctccttctccactgtcagg-3’; reverse 5’-ctggctggcttcctctactg-3’), Iba1 (for-
ward 5’-ggatttgcagggaggaaaag-3’; reverse 5’-tgggatcatcgaggaattg-3’)
were normalized to those of acidic ribosomal phosphoprotein 36B4 also referred to as P0 (for-
ward 5’-ggacccgagaagacctcctt-3’ reverse 5’-gcacatcactcagaatttcaatgg-
3’).
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Protein concentration
Determined using the Pierce BCA Protein Assay kit (Thermo Scientific1) by the microplate
procedure. Absorbance measured in EL808 Ultra Microplate Reader (BIO-TEK Instruments
Inc.) at 550nm.
Western blotting
Total cell lysates were prepared in RIPA buffer (150 mMNaCl, 50 mM Tris—HCl pH 7.4, 2
mM EDTA, 0.5% deoxycholate, 1mMNa3VO4, 20 mM NaF, 0.5%Triton X-100), supple-
mented with protease inhibitor cocktail (Roche Applied Science) and phenylmethylsulfonyl
fluoride (PMSF). Lysates were cleared by centrifugation at 4°C for 10 min at 10,000 × g. Equal
amounts of protein were subjected to electrophoresis on 10% SDS-polyacrylamide gels and
then transferred to nitrocellulose membranes (Whatman, Dassel, Germany) using an electro-
blotting apparatus (Bio-Rad Laboratories, Hercules, CA, USA). Primary antibodies used were
the polyclonal anti-Gpnmb (R&D Systems) and anti-tubulin-alpha (Cedarlane Laboratories
Limited). Matching secondary IRDye-conjugated antibodies (Westburg) were used for detec-
tion in an Odyssey V3.0 (LI-COR Inc.).
ELISA Gpnmb (mouse and human)
Levels of soluble Gpnmb (sGpnmb) were determined using mouse or human specific ELISAs
(R&D Systems).
Chitotriosidase activity
Chitotriosidase was determined as previously described [36].
Statistical Analysis
Values in figures are presented as a mean ± S.E.M. (cell experiments) or as a mean ± S.D. (ani-
mal experiments). Data were analysed by unpaired Student’s t-test or two-way ANOVA as
indicated. Soluble Gpnmb was analysed by Mann-Whitney u-test. P values< 0.05 were consid-
ered significant. Pearson correlational analysis was used to evaluate correlation as indicated.
Results
Npc1nih/nih mice progressively accumulate cholesterol and (glyco)
sphingolipids in liver and spleen
Npc1nih/nih BALB/c mice with a null allele start developing neurological symptoms such as gait
ataxia and tremors around P50. These symptoms progress rapidly, leading to the death of the
animals between 11 and 12 weeks of age. Since hepatosplenomegaly is an early indicator of
NPC, we focused our analysis on liver and spleen. In line with previous reports, we detected
symptoms of visceral disease as early as P20. A major increase in liver weight was observed in
Npc1nih/nih mice when compared with Npc1nih/+ and Npc1+/+ littermates (data not shown).
Hepatomegaly was observed at the earliest time point analysed (P20) and intensified with age.
Hematoxylin & eosin (H&E) staining of liver sections of these animals showed gradual increase
of lipid-laden cells in the centrilobular area (Fig 1A). Concomitantly, at P20 Npc1nih/nih mice
also presented a marked accumulation of total hepatic cholesterol compared to control animals
(Fig 1B). The sphingolipid ceramide (Cer) and the GSLs glucosylceramide (GlcCer), lactosyl-
ceramide (LacCer) and globotriaosylceramide (Gb3) were also significantly increased in the
liver of P20 Npc1nih/nih mice compared to Npc1+/nih and Npc1+/+ age-matched controls (Fig
Gpnmb Is a Marker for NPC
PLOSONE | DOI:10.1371/journal.pone.0147208 January 15, 2016 5 / 19
1B). Overall the accumulation of the different lipids progressed with age, reaching its maxi-
mum at end-stage between 84–90 days of age (Fig 1B).
Interestingly, H&E staining of Npc1nih/nih mice spleen also revealed a striking increase in
lipid-filled cells, which after prolonged disease progression lead to a disruption of splenic archi-
tecture (Fig 2A). In the spleen we detected a striking accumulation of several lipid species as
well (Fig 2B).
Fig 1. Progressive accumulation of cholesterol, GSLs and foam cells inNpc1nih/nihmice liver. (A) H&E staining of liver sections of Npc1+/+ and
Npc1nih/nih at 20, 40, 60 and 80 days of age. CV = central vein, PV = portal vein. Scale bar = 100 μm. (B) Levels of total cholesterol, ceramide and GSLs,
glucosylceramide, lactosylceramide and globotriaosylceramide in liver lysates ofNpc1+/+ (WT), Npc1+/nih (HET) andNpc1nih/nih (KO) mice at the age of 20–
23, 40–43, 60–63 and 84–90 days. Data (n = 6–12, mean ± S.D.) were analysed using a two-way ANOVA: *** P < 0.001 fromNpc1+/+.
doi:10.1371/journal.pone.0147208.g001
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Gpnmb is expressed in foamy lipid laden cells in liver and spleen of
Npc1nih/nih mice
In agreement with earlier work [18], we found that Gpnmb mRNA is increased in liver and
spleen of Npc1nih/nih mice (Fig 3). At P20 hepatic Gpnmb expression was already 200-fold
higher in Npc1nih/nih mice compared to age-matched Npc1+/+ animals and at end-stage this dif-
ference was over 2000-fold (Fig 3). In spleen of Npc1nih/nih mice we also observed a striking
Fig 2. Progressive accumulation of cholesterol and GSLs inNpc1nih/nihmice spleen. (A) H&E staining of spleen sections of Npc1+/+ andNpc1nih/nih at
20, 40, 60 and 80 days of age. FC = follicle centre, PALS = peri-arteriolar lymphocyte sheath, WP = white pulp, RP = red pulp. Scale bar = 100 μm. (B) Levels
of total cholesterol, ceramide and GSLs, glucosylceramide, lactosylceramide and globotriaosylceramide in spleen lysates of Npc1+/+ (WT), Npc1+/nih (HET)
andNpc1nih/nih (KO) mice at the age of 20–23, 40–43, 60–63 and 84–90 days. Data (n = 3–6, mean ± S.D.) were analysed using a two-way ANOVA: *
P < 0.05, ** P < 0.01 and *** P < 0.001 from Npc1+/+.
doi:10.1371/journal.pone.0147208.g002
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increase in Gpnmb expression levels (Fig 3). Cathepsin D expression, a marker earlier found to
be elevated in Npc1 deficient mice [20,37,38], was also increased in liver and spleen of Npc1nih/
nihmice (data not shown).
Gpnmb has been reported to be expressed in macrophages [39]. To establish whether mac-
rophages are indeed the source of elevated Gpnmb in NPC mouse tissues, we analysed the
expression levels of the macrophage marker ionized calcium-binding adapter molecule 1 (Iba-
1) in liver and spleen of the different animals. In liver of Npc1nih/nih mice we only observed a
significant increase in Iba-1 gene expression compared to controls at 84–90 days of age (Fig 3).
In spleen we did not observe increased Iba-1 mRNA expression levels (Fig 3). Expression levels
of macrophage marker F4/80 were also analysed and presented a similar pattern as Iba-1 (data
not shown).
To address the question whether Gpnmb is expressed by macrophages we performed
immunohistochemical double staining analysis for Gpnmb and Iba-1 in liver and spleen.
Gpnmb protein containing cells strongly increased in numbers with age in liver (Fig 4) and
spleen (Fig 5) of Npc1nih/nih mice. Gpnmb staining abundance per cell also increased with age.
All Gpnmb protein containing cells stained positive for Iba1 and appeared swollen, and are
therefore most likely lipid-laden macrophages. In liver at day 20, only a minority of Iba1-posi-
tive macrophages also stained positive for Gpnmb; these Iba1posGpnmbpos macrophages are
located in acinar zone 3, near the central vein, and contain lipids (Fig 4). The majority of Iba1-
posGpnmbneg macrophages are located in the more central acinar zone 2; these cells are
increased in size in comparison with Iba1posGpnmbneg macrophages in Npc1+/+ liver, but do
not seem to have accumulated lipids. With age, the number of Iba1posGpnmbpos lipid-laden
macrophages strongly increased in Npc1nih/nih liver (Fig 4), in full agreement with gene expres-
sion data.
In Npc1nih/nih spleen at day 20 (Fig 5), low numbers of IbaposGpnmbpos macrophages were
detected in the T-lymphocyte rich peri-arteriolar lymphocyte sheath area (PALS). At that
stage, lipid-containing Iba1pos macrophages were mostly present in the marginal zone
Fig 3. Gpnmb gene expression is increased with disease progression inNpc1nih/nihmice viscera.
Gpnmb (top-panel) and the macrophage marker Iba-1 (bottom-panel) gene expression relative to the house-
keeping P0 gene in liver and spleen ofNpc1+/+ (WT), Npc1+/nih (HET) andNpc1nih/nih (KO) mice at the age of
20–23, 40–43, 60–63 and 84–90 days. Data (n = 3–6, mean ± S.D.) were analysed using a two-way ANOVA:
* P < 0.05, ** P < 0.01 and *** P < 0.001 from Npc1+/+.
doi:10.1371/journal.pone.0147208.g003
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surrounding the white pulp, which encompasses the periarteriolar lymphocyte sheath and the
follicles (Fig 2A), but these cells do not express Gpnmb (Fig 5). Lipid-laden Iba1posGpnmbpos
macrophages increasingly populated the red pulp area at days 40, 60 and 80, finally leading to
disruption of the splenic architecture (Fig 2A). Remarkable, lipid-laden Iba1pos macrophages
Fig 4. Gpnmb positive cells are increased with disease progression inNpc1nih/nihmice liver. "Composite" panels show immunostaining of Gpnmb in
magenta and Iba-1 in yellow and methylgreen nuclear counterstain of liver of Npc1+/+ andNpc1nih/nih at 20, 40, 60 and 80 days of age. Brightfield scans were
analysed using spectral imaging, Iba1 and Gpnmb are displayed with a color-coded intensity scale. CV = central vein, PV = portal vein. Scale bar = 100 μm.
doi:10.1371/journal.pone.0147208.g004
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in the marginal zone remained Gpnmb negative at all stages examined. This Iba1posGpnmbneg
subset of macrophages also does not express F4/80, whereas F4/80 was detected by single
immunostain on adjacent sections in the PALS, follicle centres and red pulp area that contain
Iba1posGpnmbpos lipid-laden macrophages in Npc1nih/nihmice (not shown).
Fig 5. Gpnmb positive cells are increased with disease progression inNpc1nih/nihmice spleen. "Composite" panels show immunostaining of Gpnmb in
magenta and Iba-1 in yellow and methylgreen nuclear counterstain of spleen of Npc1+/+ andNpc1nih/nih at 20, 40, 60 and 80 days of age. Brightfield scans
were analysed using spectral imaging, Iba1 and Gpnmb are displayed with a color-coded intensity scale. Red blood cells (rbc) were imaged as well (red
colour, “composite” panels). FC = follicle centre, PALS = peri-arteriolar lymphocyte sheath, RP = red pulp. Scale bar = 100 μm.
doi:10.1371/journal.pone.0147208.g005
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PLOSONE | DOI:10.1371/journal.pone.0147208 January 15, 2016 10 / 19
RAW264.7 macrophages exposed to the U18666A compound mimic
cholesterol-sphingolipid accumulation and Gpnmb upregulation
Considering our finding that macrophages are the main Gpnmb-producing cell type in NPC
mice viscera, we performed in vitro experiments using the murine macrophage RAW264.7 cell
line. The NPC phenotype was induced in these cells using U18666A, an amphipathic steroid
drug which is widely used to block intracellular cholesterol trafficking by hindering the exit of
free cholesterol from the LE/L compartment [40,41].
Following 24 hours exposure of RAW264.7 macrophages to various concentrations (1–
10 μM) of U18666A, total cholesterol levels were already induced to maximal level with the
lowest dose of drug (Fig 6A). At the highest dose sphingosine, ceramide and dihydro-ceramide
were also increased (Fig 6B, 6C and 6E). Complex GSLs showed a U18666A dose-dependent
increase (Fig 6D and 6F). Thus, the U18666A cell model nicely mimics the lipid accumulation
observed in the viscera of Npc1nih/nih mice.
Next, we investigated whether Gpnmb is induced by U18666A. Upon 24 h incubation of
RAW264.7 cells with different concentrations of U18666A, Gpnmb was induced dose-depen-
dently both transcriptionally and at the level of protein (Fig 7A and 7B). To explore if Gpnmb
is shedded by RAW264.7 cells upon treatment with U18666A, an ELISA assay was used. Solu-
ble Gpnmb (sGpnmb) was found to be increased in a dose-dependent manner in medium of
RAW264.7 cells as well (Fig 7C).
Plasma Gpnmb levels are elevated in Npc1nih/nih mice and in NPC
patients
Next, we investigated if sGpnmb is elevated in plasma of Npc1nih/nih mice. Interestingly, we
observed an elevation of sGpnmb in plasma of the Npc1nih/nih animals, which increased over
time with disease progression (Fig 8A). At end-stage Npc1nih/nih mice displayed a 6-fold
increase in plasma sGpnmb levels compared with Npc1+/+ or Npc1nih/+ controls. Additionally,
we analysed sGpnmb levels in the plasma of the late-onset Npc1nmf164 mouse model. This
model has a point mutation in the Npc1 gene that corresponds to a single amino acid change
(D1005G) in the NPC1 protein and is more representative of the juvenile/classic form of
human disease [29]. In plasma of end-stage (110 day-old) Npc1nmf164 mice the levels of
sGpnmb were 8-fold elevated compared with age-matched controls (Fig 8B). Next we analysed
if the mouse findings could be translated to the human disease by determination of sGpnmb in
plasma of patients diagnosed with NPC not receiving Zavesca treatment. Most patients ana-
lysed suffered from the adult form of the disease (n = 12) and three suffered from the early-
infantile form (for patient information see S1 Table). Importantly, sGpnmb was found to be
significantly elevated in NPC plasma compared to healthy control individuals (Fig 8C). Plasma
of NPC carriers (one confirmed mutation) showed a trend of elevated sGpnmb (Fig 8C). Ages
between the groups analysed did not differ significantly: NPC (n = 17, age 41.3 ± 5.6
[mean ± S.E.M.]), healthy control individuals (n = 9, age 42.4 ± 2.8) and NPC carriers (n = 8,
age 47.2 ± 4.2).
Gpnmb induction in ‘NPC’ RAW264.7 is glycosphingolipid dependent
In Npc1nih/nih mice at P20 and RAW264.7 cells exposed to U18666A at the lowest concentra-
tion, cholesterol levels were already maximally elevated. Interestingly, build-up of GSLs also
occurred and Gpnmb levels seemed to follow the accumulation of GSLs. Therefore we hypoth-
esized that Gpnmb induction might be caused by lysosomal GSLs rather than cholesterol. To
this end, we used RAW264.7 cells first treated with U18666A for 8 h followed by an additional
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12 h of glucosylceramide synthase (GCS) inhibition with N-butyl-1-deoxynojirimycin
(NB-DNJ, Zavesca, 250 μM) to lower GSL levels [42]. At this concentration NB-DNJ not only
inhibits GCS, but also partially inhibits GBA and fully GBA2, both responsible for the degrada-
tion of GlcCer [43,44]. Cells treated with U18666A, in combination with NB-DNJ or not, pre-
sented comparable accumulation of total cholesterol (Fig 9A). Ceramide levels were increased
1.5 fold with the combination treatment (Fig 9A). In contrast, both GlcCer and LacCer were
reduced upon NB-DNJ treatment (Fig 9A). Of note, reducing GlcCer levels also deprives GBA
and GBA2 of substrate for degradation thus adding to the direct enzyme inhibition by
NB-DNJ. Remarkably, Gpnmb gene expression and its secretion were abrogated in the pres-
ence of NB-DNJ, suggesting that GSL (GlcCer and LacCer) accumulation, but not cholesterol
itself, is triggering Gpnmb induction (Fig 9B). Additionally, other markers for lysosomal stress
Fig 6. Total Cholesterol and GSLs accumulate in macrophages exposed to U18666A. (A) total
cholesterol, (B) ceramide, (C) sphingosine, (D) glucosylceramide (GlcCer), (E) dihydro-ceramide (Dihydro-
Cer), and (F) lactosylceramide (LacCer) levels in RAW264.7 murine macrophages exposed to 1, 5 and 10 μM
of U18666A for 24 h. Data (n = 3, mean ± S.E.M.) were analysed using an unpaired t-test. * P < 0.05, **
P < 0.01 and *** P < 0.001 from DMSO control.
doi:10.1371/journal.pone.0147208.g006
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such as cathepsin D (CtsD) and Ccl3 also showed a marked reduction upon NB-DNJ treatment
(Fig 9B).
Next, the relation between sGpnmb and GSL accumulation in the cells was analysed, by
exposing RAW264.7 macrophages to different concentrations of U18666A for 20 hours. A
dose-dependent increase of GlcCer and LacCer was observed. Interestingly, the GSL levels in
the cells significantly correlated with sGpnmb present in the medium (GlcCer: r = 0.52,
P = 0.045, Fig 10A) (LacCer: r = 0.93, P< 0.0001, Fig 10B). Liver and spleen macrophages of
Npc1nih/nih mice produce Gpnmb that possibly contributes to the pool of sGpnmb in plasma.
Therefore, we correlated splenic and hepatic GSLs with plasma sGpnmb levels. We found a
positive association between GlcCer levels and sGpnmb, which was significant in the spleen
(r = 0.66, P< 0.05, Fig 10C) and nearly significant in the liver (r = 0.49, P = 0.055, Fig 10D). As
we did not have access to human visceral tissue samples, we then determined if sGpnmb
plasma levels were related to GSLs in circulation in NPC patients. The correlation between
Fig 7. Gpnmb gene and protein expression are increased in macrophages exposed to U18666A.RAW264.7 murine macrophages were exposed to 1,
5 and 10 μM of U18666A for 24 h. (A) GpnmbmRNA levels and (B) Gpnmb protein levels. (C) Soluble Gpnmb assayed by ELISA of the cell culture medium.
Data (n = 3 mean ± S.E.M.) were analysed using an unpaired t-test. * P < 0.05, ** P < 0.01 and *** P < 0.001 from DMSO control.
doi:10.1371/journal.pone.0147208.g007
Fig 8. Soluble Gpnmb levels are increased in NPCmice and patient plasma. (A) Plasma sGpnmb levels were assayed by ELISA in plasma of Npc1+/+
(WT), Npc1+/nih (HET) andNpc1nih/nih (KO) mice at the age of 20–23, 40–43, 60–63 and 84–90 days. Data (n = 3–6, mean ± S.E.M.) were analysed using a
two-way ANOVA: * P < 0.05, ** P < 0.01 and *** P < 0.001 from Npc1+/+. (B) Plasma levels of sGpnmb inNpc1+/+ (WT) andNpc1nmf164 mice at 110 days of
age. Data (n = 3–5, mean ± S.E.M.) were analysed using an unpaired t-test: ** P < 0.01. (C) Plasma levels of sGpnmb in healthy volunteers (n = 9), carriers
of one knownmutation on theNpc1 gene (n = 8) and confirmed NPC patients (n = 17) detected by ELISA, were analysed using the Matt-Whitney u test: *
P < 0.05.
doi:10.1371/journal.pone.0147208.g008
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plasma GlcCer and sGpnmb levels almost reached significance in the patient samples analysed
(r = 0.44; P = 0.075, Fig 10E). Importantly, the levels of sGpnmb in circulation significantly cor-
related with chitotriosidase enzymatic activity (Fig 10F), a biomarker used to evaluate disease
severity and progression in Gaucher disease patients with a deficiency in lysosomal glucocereb-
rosidase [36] and also used in NPC diagnosis [45].
Discussion
Reliable biomarkers are essential to monitor disease onset, progression and therapy efficacy.
Here we report on the possible use of plasma levels of Gpnmb as marker for the lysosomal stor-
age disorder NPC. We found Gpnmb to be elevated, both in tissue and plasma of Npc1nih/nih
mice, increasing with age and disease progression. The observed induction in tissue Gpnmb
gene expression is in line with previous reports [18]. Gpnmb has been found to be highly
induced in Npc1nih/nihmouse tissue arrays and upon bio-statistical analysis connected to innate
immune response [18,20]. However, Gpnmb was not ranked as a potential disease plasma cor-
relate [18]. Our detailed immunohistochemical analysis of liver and spleen in Npc1nih/nih mice,
points towards lipid accumulating macrophages as source of sGpnmb, which was further sup-
ported by in vitro studies using RAW264.7 cells treated with U18666A to mimic the NPC phe-
notype. The driver of Gpnmb expression in RAW264.7 cells is most likely a GSL, as incubation
with the GCS inhibitor N-butyl-1-deoxynojirimycin (NB-DNJ, Zavesca), the only EMA-
approved drug for the treatment of NPC, lowered GSLs such as GlcCer and LacCer and con-
comitantly Gpnmb, while not lowering cholesterol levels.
Fig 9. GSL synthesis inhibition abrogates Gpnmb induction. (A) Total cholesterol, ceramide, glucosylceramide (GlcCer) and lactosylceramide (LacCer)
levels of RAW264.7 murine macrophages exposed to 10 μMU18666A and/or 250 μMNB-DNJ for 20 h. (B) Gpnmb, Ccl3 and Cathepsin D (CtsD) gene
expression, and sGpnmb levels of RAW264.7 cells exposed to 10 μMU18666A and/or 250 μMNB-DNJ for 20 h. Data (n = 3 mean ± S.E.M.) were analysed
using an unpaired t-test. * P < 0.05, ** P < 0.01 and *** P < 0.001.
doi:10.1371/journal.pone.0147208.g009
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Additional evidence for a possible role of increased lysosomal lipid pressure in driving
Gpnmb expression stems from the observation of Gpnmb-positive cells in the immunohisto-
chemical analysis. In liver of Npc1nih/nih mice, the number of Gpnmb-positive lipid-laden mac-
rophages strongly increased with age. In the spleen, the macrophages undergoing the highest
lipid pressure, the red pulp macrophages, were the predominant Gpnmb-positive cell popula-
tions. Red pulp macrophage Gpnmb staining has also been previously observed by others [46].
At this site dysfunctional erythrocytes are cleared from the circulation, thus provoking a high
rate of intracellular lipid catabolism. In line with histological observations, we found a positive
correlation between plasma sGpnmb and splenic/hepatic GSLs levels, suggesting that the mac-
rophages in these organs substantially contribute to the secreted Gpnmb levels. Additionally,
we found sGpnmb to be elevated in a mouse model of the more common juvenile/classic form
of the disease, the Npc1nmf164 model.
Importantly, in human subjects suffering from NPC disease sGpnmb was also found to be
elevated. This needs to be interpreted with caution as the patient group numbers are limited.
GSL levels almost significantly correlated with sGpnmb in patient plasma. Of note, the
Fig 10. Correlation between glycosphingolipids and sGpnmb levels.Correlation between cell lysate (A)
glucosylceramide (GlcCer) or (B) lactosylceramide (LacCer) and sGpnmb from the medium of RAW264.7
cells exposed to 1.25, 2.5, 5 and 10 μM of U18666A for 20 h. Correlation between tissue lysate (C) hepatic or
(D) splenic GlcCer levels and plasma sGpnmb of Npc1nih/nih mice at the age of 20–23, 40–43, 60–63 and 84–
90 days. Correlation between plasma (E) GlcCer or (F) chitotriosidase activity and sGpnmb levels from
diagnosed NPC patients (n = 17). Pearson correlational analysis was used to evaluate correlation.
doi:10.1371/journal.pone.0147208.g010
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sGpnmb values correlated nicely with chitotriosidase a well-known macrophage derived LSD
marker, which has also been found to be elevated in NPC patients [45]. Correlation of sGpnmb
was also observed with CCL18, a chemokine reported to be elevated in GD [47], and oxysterols,
cholesterol oxidation products and established specific biomarkers for NPC [17] (S1 Table).
The presence of a soluble form of Gpnmb in NPC is not surprising as several in vitro studies
already pointed towards the existence of shedded variants of Gpnmb. This was for instance
reported in C2C12 myoblasts, melanocytic cells, astrocytes and breast cancer cells [25–28].
Furthermore, in a mouse model of GD, a LSD characterized by a deficient lysosomal acid β-
glucosidase (GBA) enzyme causing accumulation of GlcCer levels and derivatives, spleen and
hepatic Gpnmb gene expression levels were also found to be elevated [48]. Gpnmb was specu-
lated to serve as potential biomarker [48] and recently elevated levels of Gpnmb have been
demonstrated in cerebrospinal fluid (CSF) of a GD mouse model and in CSF of neuropathic
GD patients [49]. Of interest we have also found sGpnmb levels to be massively elevated in
Gaucher patient plasma (to be published by van Eijk et al.). sGpnmb is therefore not a disease
specific marker but rather appears to reflect the GSL load, in particular GlcCer, in macro-
phages. In this context it is important to note that lysosomal GlcCer accumulation has been
shown to increase lysosomal pH [50].
Another condition associated with lysosomal alterations is obesity [51]. We have recently
shown that Gpnmb is elevated in white adipose tissue macrophages of obese mice and obese
subjects [35]. Cholesterol-induced lysosomal stress as observed in LDLR-/- mice fed a western
type diet revealed elevated hepatic Gpnmb levels (300-fold) and this was reversed upon GCS
inhibition [52]. Taken all data together we propose that cholesterol accumulation is accompa-
nied by GSL build-up, which in turn perturbs lysosomal function in Npc1-deficient macro-
phages driving Gpnmb induction. Our data indicate that macrophages from the liver and
spleen are a considerable source of the sGpnmb found in plasma. Nonetheless, we cannot
exclude a contribution of neurologically derived sGpnmb, since astrocytes have been shown to
secrete Gpnmb [28] and sGpnmb can be detected in the CSF of GD patients [49]. In that
regard, we found Gpnmb expression to also be elevated in the cerebellum of Npc1-deficient
mice compared to wt, being mostly expressed by Iba1-positive microglial cells (S1 Fig).
Our study demonstrates that sGpnmb is a potential plasma marker to follow disease pro-
gression in NPC mice. Of note, we show that sGpnmb responds to NB-DNJ treatment in vitro,
making it a potential candidate for assessing substrate reduction therapy efficacy. The signifi-
cant elevation of sGpnmb in human NPC is promising and warrants additional analysis in a
larger cohort to establish its role as a potential new marker.
Supporting Information
S1 Fig. Gpnmb is increased in the cerebellum of Npc1nih/nih mice. Sagittal cerebellar sections
of 85-days-old wt and Npc1nih/nihmice immunostained with antibodies against Gpnmb (blue)
and Iba-1 (red). Scale bar = 1 mm (top panel), 200 μm (middle panel) and 50 μm (bottom
panel).
(TIF)
S1 Table. Clinical information of NPC patients. The status of affected or carrier of NPC dis-
ease was determined after the exomic sequencing of NPC1 and NPC2 genes, according to the
presence of two or one mutations, respectively. Filipin stainings of fibroblasts were conducted
to complete the diagnosis. Samples in red are NPC patients and samples in light red are
patients with uncertain diagnosis.
(XLS)
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